Company intelligence / Profile preview

Humeca

Ownership: Private
Development stage: Other

Overview

Humeca’s MEEK micrografting technique enables significant expansion of donor skin—up to a ratio of 1:9—allowing treatment of extensive burns with limited donor tissue. Clinical results are reported as excellent even in challenging wound beds, with fast epithelialization and high graft take rates. The company’s products are widely used in burn centers worldwide.

Therapeutic areas: Dermatology
Modalities: Device (skin grafting devices and accessories)
Industry: Surgical Medical Devices

Partnerships

Mylan/UDL Laboratories – exclusive distribution partnership to expand burn/wound care portfolio in select markets

Beyond the preview

Go deeper on Humeca.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Humeca.

Explore the full profile